Department of Ophthalmology, College of Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Department of Ophthalmology, College of Medicine; Department of Ophthalmology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Indian J Ophthalmol. 2019 Aug;67(8):1297-1302. doi: 10.4103/ijo.IJO_2100_18.
To compare the lipid layer thickness (LLT) using the LipiView® ocular surface interferometer (TearScience® Inc, Morrisville, NC) between the eye treated with glaucoma medication and untreated normal eye in the unilateral glaucoma patients, and evaluate the effect of topical glaucoma medication on the LLT parameters in glaucoma eyes.
The participants in this cross-sectional comparative study were unilateral glaucoma patients treated with topical glaucoma medications for more than 12 months. Three LLT parameters (average, minimum, and maximum) obtained by the LipiView® were compared between the glaucomatous eye and normal eye. The factors associated with LLT parameters in the eyes treated with glaucoma medication were investigated with multiple regression analysis.
Thirty patients with unilateral normal tension glaucoma were enrolled in the present study. Lipid layer average, minimum, and maximum were 64.83 ± 16.50, 51.63 ± 16.73, and 82.53 ± 20.62 in glaucomatous eyes, 77.26 ± 17.81, 62.83 ± 20.99, and 86.13 ± 15.42 in normal eyes. Lipid layer average and minimum were significantly thinner than those in normal eyes (P < 0.001, P < 0.001, respectively). Longer duration of glaucoma eye drops and a greater number of glaucoma medications were associated with the lower LLT average (β = -0.456, P < 0.001, β = -8.517, P = 0.003, respectively), and increasing glaucoma medications have a significant correlation with lower LLT minimum in glaucoma eyes (β = -8.814, P = 0.026).
The present study highlights that patients with long-term glaucoma medications need to be assessed for LLT parameters objectively evaluate their ocular surface health.
使用 LipiView® 眼表面干涉仪（TearScience® Inc，Morrisville，NC）比较单侧青光眼患者治疗眼和未治疗正常眼的脂质层厚度（LLT），并评估局部青光眼药物对青光眼眼中 LLT 参数的影响。
本横断面对比研究的参与者为接受局部青光眼药物治疗超过 12 个月的单侧青光眼患者。比较 LipiView® 获得的三个 LLT 参数（平均值、最小值和最大值）在青光眼眼中和正常眼中的差异。使用多元回归分析调查与接受青光眼药物治疗的眼睛的 LLT 参数相关的因素。
本研究纳入了 30 例单侧正常眼压性青光眼患者。青光眼眼中的脂质层平均值、最小值和最大值分别为 64.83±16.50、51.63±16.73 和 82.53±20.62，正常眼中分别为 77.26±17.81、62.83±20.99 和 86.13±15.42。青光眼眼中的脂质层平均值和最小值明显较正常眼薄（P<0.001，P<0.001）。青光眼眼药水使用时间较长和使用的青光眼药物数量较多与 LLT 平均值较低相关（β=-0.456，P<0.001，β=-8.517，P=0.003），使用的青光眼药物数量增加与青光眼眼中 LLT 最小值较低显著相关（β=-8.814，P=0.026）。
本研究强调，长期使用青光眼药物的患者需要客观评估 LLT 参数，以评估其眼表面健康状况。
